Medication info
Candeloran 5/16 mg (Rosuvastatin, Candesartan)

Candeloran 5/16 mg (Rosuvastatin, Candesartan)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP X 3)]
Approval status
Active

MFDS item code 202008717 · Approved 2020.12.11 · Insurance code 657808180

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience of administration.
Child dose
○ Candesartan cilexetil Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. ○ Candesartan cilexetil Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • impaired left ventricular systolic function
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This medication is used for patients who need to take both Candesartan Cilexetil and Rosuvastatin simultaneously. Candesartan Cilexetil is primarily used by patients with essential hypertension and is also used in patients with heart failure who have impaired left ventricular function. It serves as an adjunct therapy when treatment with ACE inhibitors is insufficient or when tolerance is poor. Rosuvastatin helps when dietary control and exercise are insufficient to manage hypercholesterolemia and mixed dyslipidemia. Additionally, it is used as an adjunctive treatment for patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. Above all, this medication effectively lowers blood cholesterol levels, slows the progression of atherosclerosis, and reduces the risk of cardiovascular disease. Therefore, it is used to improve blood pressure and cholesterol management.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No initial dose adjustment is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience with use in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience with use in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No initial dose adjustment is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same amounts of each active ingredient) for convenience of administration.

Child dose

○ Candesartan cilexetil Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. ○ Candesartan cilexetil Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication should not be used by pregnant women. Taking it during pregnancy can cause serious harm to the fetus and newborn. It should not be administered to patients who are allergic to this medication, have severely impaired liver function, or have certain muscle disorders. Moreover, caution is necessary for patients with severely reduced kidney function or those taking certain medications concurrently, as it may pose additional risks. Elderly patients or those with compromised liver function should be particularly cautious when taking this medication, and it is advisable to monitor liver and kidney function regularly through blood tests. If symptoms of muscle pain or weakness occur, consult a doctor immediately, and in severe cases, discontinuation of the medication may be necessary. As this medication lowers blood pressure, symptoms of hypotension such as dizziness or fatigue may occur, requiring caution when driving or operating machinery. There may be drug interactions, so if you are taking other medications, be sure to inform your doctor or pharmacist. Women of childbearing potential should use appropriate contraceptive methods while taking this medication, and if pregnancy is confirmed, the medication should be discontinued immediately. Breastfeeding women should avoid taking this medication, or if necessary, discontinue breastfeeding while taking it. This medication is not recommended for children as its safety and efficacy have not been sufficiently established in this population. In case of overdose, seek medical attention immediately for appropriate treatment and monitor blood pressure and heart condition according to symptoms. Store this medication in a tightly closed container to prevent exposure to air or moisture, and keep it at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain its effectiveness for an extended period.

Side effects

Headache, nasopharyngitis, local infection, fatigue, systemic itching, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood glucose, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, positional dizziness, miliaria, periodontitis, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, nausea, increased blood glucose, decreased serum sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, constipation, abdominal pain, pancreatitis, vascular edematous response including hypersensitivity, dizziness, low back pain, respiratory infection, upper respiratory tract infection, pharyngitis, rhinitis, fatigue, peripheral edema, chest pain, bronchitis, cough, sinusitis, nausea, abdominal pain, diarrhea, vomiting, arthralgia, proteinuria, weakness, fever, paresthesia, dyspepsia, gastroenteritis, tachycardia, palpitations, increased creatine kinase, hyperglycemia, hypertriglyceridemia, hyperuricemia, myalgia, epistaxis, anxiety, depression, somnolence, dyspnea, rash, increased sweating, hematuria, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral neck fracture, contusion, unstable angina, idiopathic pulmonary fibrosis, wet cough, worsening hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disturbances, decreased libido, memory loss, loss of appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, acute kidney failure, myalgia, arthralgia, increased CK, dizziness, increased ALT, fatigue, numbness, sensory disturbance, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, thrombocytopenia, increased serum creatinine, vascular edema, increased blood pressure, hypotension, tachycardia, symptomatic hypotension, increased serum potassium, increased serum creatinine concentration, decreased blood pressure, shock, syncope, loss of consciousness, intestinal vascular edema, jaundice, hepatitis, liver dysfunction, urticaria, vascular edema, myalgia, weakness, increased CK, elevated serum and urinary myoglobin, rhabdomyolysis, arthralgia, myalgia, low back pain, renal impairment, acute kidney failure, interstitial pneumonia, shock, syncope, loss of consciousness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated with drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe myasthenia gravis, oculobulbar myasthenia gravis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture, and it should be kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps to maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP X 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.